Oxford Outcomes & ICON Team Presentations - ICON plc

An ICON plc Company
ISPOR 14 th Annual European Congress 2011
Oxford Outcomes & ICON Team Presentations
Date Format Title Presenter(s)
Saturday 5 November
9:00 - 13.00
Workshop
Introduction to Patient Reported Outcomes:
Instrument Development & Evaluation
Andrew Lloyd, Vice President, Patient Reported Outcomes
Annabel Nixon, Director, Patient Reported Outcomes
Sarah Acaster, Director, Patient Reported Outcomes
Saturday 5 November
9:00 - 13.00
Workshop
Statistical Methods for Pharmacoeconomics &
Outcomes Research
Andrew Briggs, Senior Scientific Advisor
Neil Hawkins, Vice President, Health Economics
Saturday 5 November
14.00 - 18.00
Workshop
Meta-Analysis and Systematic Literature Review
Neil Hawkins, Vice President, Health Economics
Olivia Wu, University of Glasgow
Sunday 6 November
12.30 - 14.15
First Plenary Session
Pros and Cons of a Centralised European Pricing &
Reimbursement Agency
Moderator: Mark J Sculpher, ISPOR President, Professor of
Health Economics, Centre for Health Economics, University of
York, and Senior Scientific Advisor, Oxford Outcomes an ICON Plc
company.
Speakers: Hans-Georg Eichler, Professor & Senior Medical Officer,
European Medicines Agency and CBI Visiting Scholar and Robert
E. Wilhelm Fellow, Massachusetts Institute of Technology, London,
Adrian Towse, Director, Office of Health Economics, London
Sunday 6 November
14.45 - 15.45
Issue Panel
Valuing diagnostics: Do we need different metrics?
Moderator: Peter J. Neumann, ScD, Professor & Director,
The Center for the Evaluation of Value and Risk in Health
Panelists:
Mark J Sculpher, Senior Scientific Advisor, Oxford Outcomes an
ICON Plc company
Manuel Garcia-Goni, Associate Professor, Applied Economics,
University of Madrid
Sunday 6 November
16.00 - 17.00
Workshop
Mixing Modes of Patient-Reported Outcomes
Data Collection in Clinical Trials: ISPOR PRO
Good Research Practice Task Force report
recommendations
Discussion Leaders: Stephen Joel Coons, Executive Director, PRO
Consortium, Critical Path Institute, Andrew Lloyd, Vice President,
PRO, Oxford Outcomes an ICON Plc company, Sonya Eremenco,
ePRO Manager, UBC, Jean Paty, Founder & Senior Vice President,
Scientific, Quality & Regulatory Affairs, Invivodata
Sunday 6 November
16.00 - 17.00
Workshop
Moving towards Value Based Health Care in different
constituencies, a presentation on behalf of the ISPOR
Value Based Health Care special interest group
Rachael Fleurence, Director, Health Economics, Oxford
Outcomes an ICON Plc company
Edward Kim, Executive Director, HEOR, Novartis
Eldon Spackman, Research Fellow, Centre for Health Economics,
University of York
Huseyin Naci, PhD Candidate, London School of Economics
Sunday 6 November
17.15 - 18.15
Workshop
Does Observational Research support the goals of
Comparative Effectiveness Research
Rachael Fleurence, Director, Health Economics, Oxford
Outcomes an ICON Plc company
Alex Exuzides, Director, Statistical Analysis, ICON Plc
Hannah Patrick, Consultant Clinical Advisor to the IP Program,
NICE
Sunday 6 November
17.15 - 18.15
Workshop
A review of the technical support documents for
the application of NICE methods guidance on the
measurement and valuation of health
Discussion Leaders: John Brazier, PhD, Professor, School of
Health and Related Research (ScHARR), University of Sheffield,
Sheffield, UK; Louise Longworth, PhD, Reader in Health
Economics, Health Economics Research Group, Brunel University,
Uxbridge, UK; Roberta Ara, MSc, Research Fellow, School of
Health and Related Research (ScHARR), University of Sheffield,
Sheffield, UK; Andrew Lloyd, DPhil, Vice President (Practice
Lead), Oxford Outcomes, Oxford, UK
Sunday 6 November
Poster
Cost-effectiveness analysis of cardiac
resynchronization therapy in patients with
asymptomatic to mild heart failure based on the
European cohort of the reverse study from the Spanish
health system perspective
Stuart Mealing, Senior Health Economist
Sunday 6 November
Poster
Optar Study: Transcatheter aortic valve implantation
(TAVI) versus optimal medical treatment (OMT) in
prohibitive surgical risk patients with severe aortic
stenosis (AS) ‐ An exploratory cost-effectiveness
analysis
James Eaton, Lead Market Access Researcher
Sunday 6 November
Poster
Conceptual model of the impact of hip fracture on
patients' lives
Cicely Kerr, Outcomes Researcher
Sunday 6 November
Poster
A mixed-effects piecewise linear model of the rate of
lung function decline before and after the clinical use
of dornase alfa in an observational study of cystic
fibrosis
Lawrence Rasouliyan, Senior Research Manager, Statistical
Analysis
David Pasta, Vice President, Statistical Analysis
Stefanie Silva, Associate Director, Statistical Analysis
Sunday 6 November
Poster
Estimating the net health benefits of intramuscular
interferon beta-1A and fingolimod in treating patients
with relapsing-remitting multiple sclerosis
Shelagh Szabo, Director, Epidemiology
Sunday 6 November
Poster
A simulation model of the effects of treatments
for secondary hyperparathyroidism on mortality
Andrew Briggs, Senior Scientific Advisor, Oxford Outcomes an
ICON Plc company, Lindsay Chair in Health Policy & Economic
Evaluation, Public Health & Health Policy, University of Glasgow
Sunday 6 November
Poster
Comparing projected outcomes of renal transplant
recipients based on trial endpoint
of renal function and receiving different
immunosuppressive regimens in the United States
Andrew Briggs, Senior Scientific Advisor, Oxford Outcomes an
ICON Plc company, Lindsay Chair in Health Policy & Economic
Evaluation, Public Health & Health Policy, University of Glasgow
Sunday 6 November
Poster
Factors associated with utility and disutility values in
relapsing form of multiple sclerosis (RMS) Patients
using data from temso, a teriflunomide pivotal phase III
trial
Andrew Briggs, Senior Scientific Advisor, Oxford Outcomes an
ICON Plc company, Lindsay Chair in Health Policy & Economic
Evaluation, Public Health & Health Policy, University of Glasgow
Sunday 6 November
Poster
Cost-effectiveness of denosumab in the treatment of
postmenopausal osteoporosis in Scotland
Davies A 1 , Compston J 2 , Ferguson S 3 , McClosky E 4 , Shearer
A 5 , Taylor A 5 1 Oxford Outcomes Ltd. (UK), Oxford, Oxfordshire,
UK, 2 Cambridge University Hospitals NHS Foundation Trust,
Cambridge , UK, 3 Amgen Limited, Uxbridge , UK, 4 University of
Sheffield, Sheffield , UK, 5 Amgen Limited, Cambridge, UK
Sunday 6 November
Poster
Complicated parkinson’s disease: discrete choice
analysis to assess patients’ preferences. A pilot study
Lloyd AJ 1 , Herdman M 2 , Gonzalez P 3
1
Oxford Outcomes Ltd., an ICON plc Company, Oxford , Oxon,
UK, 2 Insight Consulting & Research, Mataro, Spain, 3 Medtronic
Iberia, Madrid, Spain

An ICON plc Company
ISPOR 14 th Annual European Congress 2011
Oxford Outcomes & ICON Team Presentations
Date Format Title Presenter(s)
Monday 7 November
11.30 - 12.30
Research Podium
Presentation
Mean versus median overall survival (OS) for
describing value of new cancer therapies: a case
study
Davies A 1 , Briggs A 1 , Wagner S 2 , Kotapati S 2 , Schneider J 1 ,
Obeid O 1 , Levy AR 1 . 1 Oxford Outcomes an ICON Plc.
Company, 2 BMS Pharmaceuticals
Monday 7 November
11.30 - 12.30
Monday 7 November
14.00 - 15.00
Monday 7 November
15.15 - 16.15
Monday 7 November
15.15 - 16.15
Monday 7 November
16.30 - 17.30
Monday 7 November
Monday 7 November
Research Podium
Presentation
Workshop
Research Podium
Presentation
Research Podium
Presentation
Research Podium
Presentation
Poster
Poster
New approaches for effective use of data:
better synthesis and enhanced power
What can patient preference studies tell us about
patient adherence? A novel insight into an old
problem
Impact of the choice of prior distribution on relative
effect sizes using Bayesian network meta-analysis
Economic evaluation in niche markets: the role of
the UK's advisory group for national specialised
services for rare diseases and disorders
The value of heterogeneity for cost-effectiveness
subgroup analysis: theoretical framework and
application
Improving Global Vascular Risk Management
(GVRM) using the cosehc cardiovascular risk
assessment tool
Current treatments for chronic hepatitis B: A
systematic review
Andrew Briggs, Senior Scientific Advisor, Oxford Outcomes
an ICON Plc company, Lindsay Chair in Health Policy &
Economic Evaluation, Public Health & Health Policy, University
of Glasgow
Andrew Lloyd, Vice President, PRO, Oxford Outcomes an
ICON Plc company
A Brett Hauber, Senior Economist and Vice President
RTI Health Solutions
John F.P. Bridges, Assistant Professor, Department of Policy
& Management, John Hopkins Bloomberg School of Public
Health, Baltimore, MD
Goring S 1 , Ghement I 2 , Kalsekar A 2 , L’Italian G 2 , Levy A 1
1
Oxford Outcomes an ICON Plc. company 2 BMS and Yale
School of Medicine
Khan N 1 , Kiss N 1 , Pang F 2 1 Oxford Outcomes an ICON Plc.
Company 2 Shire Human Genetic Therapies
Espinoza M, Manca A, Claxton K, Sculpher MJ
Alex Exuzides, Director, Statistical Analysis
Chris Colby, Research Scientist
Stuart Mealing, Senior Health Economist
Monday 7 November Poster A review of the NICE appeals process James Eaton, Lead Market Access Researcher
Monday 7 November
Poster
The translation and linguistic validation of the
treatment related impact measure - weight (TRIM-
Weight)
Monday 7 November Poster A typology of outcomes for health research
Gareth Ellis, Director, Translation Services
Andrew Briggs, Senior Scientific Advisor, Oxford Outcomes
an ICON Plc company, Lindsay Chair in Health Policy &
Economic Evaluation, Public Health & Health Policy, University
of Glasgow, Adrian Levy, Senior Scientific Advisor, Oxford
Outcomes an ICON Plc company, Department of Community
Health and Epidemiology, Dalhousie University
Tuesday 8 November
08.30 - 9.30
ISPOR Forum
Good research practices for modeling by ISPOR
Modeling Good Research Practices Task Force
J. Jaime Caro, MDCM, FRCPC, FACP, Senior Vice Presi dent,
Research, United BioSource Corporation; Andrew Briggs,
DPhil, Lindsay Chair in Health Policy & Economic Evaluation,
Public Health & Health Policy, University of Glasgow, Senior
Scientific Advisor, Oxford Outcomes an ICON Plc company,
Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health,
UMIT – University of Health Sciences, Medical Informatics &
Technology.
Tuesday 8 November
10.00 - 11.00
Issues Panel
Multi-criteria decision analysis: an appropriate
framework for decision-making about new
medical technologies?
Sculpher MJ, Devlin N, Peacock S, Boysen M
Tuesday 8 November
14.45 - 15.45
Workshop
Model Busting: Methods and Experience in the
critical appraisal of Cost-Effectiveness Models
submitted to reimbursement agencies
Rachael Fleurence, Director, Health Economics, Oxford
Outcomes an ICON Plc. company, Eldon Spackman, Research
Fellow, Center for Health Economics, University of York,
Susan Griffin, Research Fellow, Center for Health Economics,
University of York, Edward Kim, Executive Director, HEOR,
Novartis Pharmaceuticals Corporation.
Tuesday 8 November
Poster
A retrospective longitudinal study of treatment
patterns and outcomes among patients with
unresectable stage IIIc/IV melanoma in Canada
(Melody)
Shelagh Szabo, Director, Epidemiology
Kathy Osenenko, Epidemiologist
Tuesday 8 November
Poster
The use of parametric survival analysis to predict
progression free and overall survival of newly
diagnosed chronic myeloid leukemia (CML) patients
Stuart Mealing, Senior Health Economist
Tuesday 8 November
Poster
Impact of dry eye on everyday life (IDEEL) -
symptom bother: Estimating cut-off scores for dry
eye severity groups
Sarah Acaster, Director, Patient Reported Outcomes
Tuesday 8 November
Poster
Estimation of meaningful change on the skindex-29
and dermatology life quality index in patients with
chronic hand eczema
Augustin M 1 , Lloyd AJ 2 , Purwins S 1 , Diepgen TL 3
1
University Clinics of Hamburg, Hamburg, Germany, 2 Oxford
Outcomes, an ICON plc Company, Oxford , Oxon, United
Kingdom, 3 University Heidelberg, Heidelberg, Germany
Tuesday 8 November
Poster
Economic impact of healthcare resource utilisation
patterns among patients diagnosed with advanced
melanoma in the UK, Italy, and France: Results
from a retrospective, longitudinal survey (Melody
Study)
Karissa Johnston, Epidemiology, Oxford Outcomes an ICON
Plc company, Marc van Baardewijk, BMS.
Tuesday 8 November
Poster
Elicitation of health state utilities in neuroendocrine
tumours
Swinburn P1, Chandiwana D 2 , Quadri N1, Wang X 3 , Lloyd
AJ 1 1 Oxford Outcomes Ltd., an ICON plc Company, Oxford,
Oxon, UK, 2 Novartis Pharmaceuticals UK Limited, Surrey, UK,
3
Novartis Pharmaceuticals Corporation, Florham Park, NJ,
USA